Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1369459 | Bioorganic & Medicinal Chemistry Letters | 2012 | 6 Pages |
A series of novel 6-methoxy-2-(piperazin-1-yl)-4H-chromen-4-one and 5,7-dimethoxy-2-(piperazin-1-ylmethyl)-4H-chromen-4-one derivatives of biological interest were prepared and screened for their pro-inflammatory cytokines (TNF-α and IL-6) and antimicrobial activity (antibacterial and antifungal). Among all the compound screened (5a–j and 10k–t), the compounds 5c, 5g, 5h, 10l, 10m, 10n and 10r found to have promising anti-inflammatory activity (up to 65–87% TNF-α and 70–93% IL-6 inhibitory activity) at concentration of 10 μM with reference to standard dexamethasone (71% TNF-a and 84% IL-6 inhibitory activities at 1 μM) while the compounds 5b, 5i, 5j, 10s and 10t found to be potent antimicrobial agent showing even 2 to 2.5-fold more potency than that of standard ciprofloxacin and miconazole at the same MIC value of 10 μg/mL.
Graphical abstractA series of novel 6-methoxy-2-(piperazin-1-yl)-4H-chromen-4-one and 5,7-dimethoxy-2-(piperazin-1-ylmethyl)-4H-chromen-4-one derivatives of biological interest have been designed and synthesized. All the new compounds were evaluated for anti-inflammatory activity (TNF-α and IL-6 inhibitory activity) and antimicrobial (antifungal and antibacterial) activities against some selected pathogenic bacteria and fungi.Figure optionsDownload full-size imageDownload as PowerPoint slide